Comments on: Vasa Adhatoda vasica: Respiratory Herb with 2026 Antiviral Research Data

By: Matthew Green

Matthew Green — Thu, 17 Sep 2026 13:30:46 +0000

I look forward to seeing the Phase II/III trials that ICMR and academic centers plan for 2026 to 2027 on RSV and influenza.

Ashley Carter — Sun, 13 Sep 2026 14:34:56 +0000

The 2025 neuraminidase IC50 for vasicine against H1N1 being eighteen point four micromolar shows moderate activity compared to oseltamivir.

Rebecca Turner — Wed, 09 Sep 2026 08:44:14 +0000

Combining Vasa with Pippali to boost vasicine absorption by about thirty percent aligns with what I’ve seen in other bioavailability studies.

Brian Cooper — Sat, 05 Sep 2026 18:05:29 +0000

The nanoformulation work using chitosan nanoparticles for inhaled vasicine seems promising for bypassing first pass metabolism.

Susan Clark — Tue, 01 Sep 2026 14:21:07 +0000

Safety margins for pregnant individuals remain unclear; the article notes oxytocic effects but doesn’t give a specific dose threshold.

Andrew Collins — Fri, 28 Aug 2026 09:44:17 +0000

The historical note about Charaka and Sushruta classifying Vasa for Pranavaha Srotas grounds the modern findings nicely.

Rachel Adams — Mon, 24 Aug 2026 18:07:28 +0000

Seeing the NLRP3 inhibition data makes me think about potential adjunct use during severe viral pneumonitis.

Nicole Hayes — Thu, 20 Aug 2026 13:59:30 +0000

Did the 2026 preprint on RSV mention any follow up in vivo studies planned?

Tom Wilson — Sun, 16 Aug 2026 11:00:05 +0000

The idea that goats avoid the plant because of its alkaloid content is a neat ecological hint at potency.

Pallavi Chatterjee — Fri, 14 Aug 2026 22:51:12 +0000

Thanks!